Biomea Fusion’s icovamenib shows efficacy in Type 2 diabetes trial
Biomea Fusion (BMEA) announced its presentations at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management in ...
Biomea Fusion, Inc. (NASDAQ:BMEA) Shares Sold by GSA Capital Partners LLP
GSA Capital Partners LLP lowered its stake in shares of Biomea Fusion, Inc. (NASDAQ:BMEA – Free Report) by 36.8% during the third quarter, according to the company in its most recent disclosure with ...
We're A Little Worried About Biomea Fusion's (NASDAQ:BMEA) Cash Burn Rate
Having said that, unprofitable companies are risky because they could potentially burn through all their cash and become distressed. So, the natural question for Biomea Fusion (NASDAQ:BMEA) ...
ETF Daily News14d
Biomea Fusion FY2024 EPS Estimate Increased by HC Wainwright
Biomea Fusion, Inc. (NASDAQ:BMEA – Free Report) – Investment analysts at HC Wainwright lifted their FY2024 earnings estimates for shares of Biomea Fusion in a research note issued on Thursday ...
Investing15d
Biomea Fusion's SWOT analysis: clinical hold clouds diabetes drug stock outlook
Biomea Fusion Inc. (NASDAQ:BMEA), a biotechnology company focused on developing innovative treatments for diabetes and obesity, finds itself at a critical juncture as it navigates regulatory ...
Investing15d
Biomea Fusion's SWOT analysis: clinical hold clouds diabetes drug stock outlook
Biomea Fusion Inc. (NASDAQ:BMEA), a biotechnology company focused on developing innovative treatments for diabetes and obesity, finds itself at a critical juncture as it navigates regulatory ...
Finanznachrichten18d
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Zeit Aktuelle Nachrichten 05.11. Biomea Fusion's SWOT analysis: clinical hold clouds diabetes drug stock outlook 01.11. Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635 ...
Stockhouse18d
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) (“Biomea” or the “Company”), a clinical stage biopharmaceutical ...